Originally published In Press as doi:10.1074/jbc.M112440200 on March 13, 2002
J. Biol. Chem., Vol. 277, Issue 23, 20284-20292, June 7, 2002
Histone Acetylation in Vivo at the Osteocalcin Locus
Is Functionally Linked to Vitamin D-dependent, Bone
Tissue-specific Transcription*
Jiali
Shen
,
Martin
Montecino§,
Jane B.
Lian
,
Gary S.
Stein
,
Andre J.
van Wijnen
, and
Janet L.
Stein
¶
From the
Department of Cell Biology, University of
Massachusetts Medical School, Worcester, Massachusetts 01655 and
§ Departamento de Biologia Molecular, Universidad de
Concepcion, Concepcion, Chile
Received for publication, December 28, 2001, and in revised form, February 13, 2002
 |
ABSTRACT |
The accessibility of regulatory elements in
chromatin represents a principal rate-limiting parameter of gene
transcription and is modulated by enzymatic transcriptional co-factors
that alter the topology of chromatin or covalently modify histones (e.g. by acetylation). The bone-specific activation and
1,25-dihydroxyvitamin D3 enhancement of osteocalcin
(OC) gene transcription are both functionally linked to modifications
in nucleosomal organization. The initiation of tissue-specific basal
transcription is accompanied by the induction of two DNase I
hypersensitive sites, and this chromatin remodeling event requires
binding of the key osteogenic factor RUNX2/CBFA1 to the OC promoter.
Here, we analyzed the acetylation status of histones H3 and H4 when the
OC gene is active (in osteoblastic ROS17/2.8 cells) or inactive (in
fibroblastic ROS24/1 cells) using chromatin immunoprecipitation assays.
We find that acetylated histone H3 and H4 proteins are associated
with the OC promoter only when the gene is transcriptionally active and
that the acetylation status is relatively uniform across the OC locus
under basal conditions. Acetylation of H4 at the OC gene is selectively
increased following vitamin D3 enhancement of OC
transcription, with the most prominent changes occurring in the region
between the vitamin D3 enhancer and basal promoter. Thus,
our results suggest functional linkage of H3 and H4 acetylation in
specific regions of the OC promoter to chromatin remodeling that
accompanies tissue-specific transcriptional activation and vitamin D
enhancement of OC gene expression. These findings provide mechanistic
insights into bone-specific gene activation within a native genomic
context in response to steroid hormone-related regulatory cues.
 |
INTRODUCTION |
Steroid hormones and retinoids (e.g.
(1,25)-dihydroxyvitamin D3, glucocorticoid, retinoic acid)
modulate bone formation and remodeling in vivo at least in
part by controlling proliferation and/or differentiation of osteoblasts
(1-3). These ligands regulate transcription of genes in osseous cells
through receptors that bind as heterodimers to cognate response
elements in the promoters of bone related genes (4-6). The vitamin
D3 receptor
(VDR)1 is a principal
regulator of the bone-related osteocalcin (OC) gene and interacts
together with the retinoid X receptor to a vitamin D3
response element (VDRE) located in a distal enhancer region (7-14).
Transcriptional enhancement of OC gene expression in response to
vitamin D3 occurs only after basal tissue-specific transcription is initiated in osteoblasts through bone-specific factors
(1, 15, 16). The basal activation of the OC gene involves conversion of
silent closed chromatin to active open chromatin concomitant with
increased accessibility of the OC gene promoter to cognate
transcription factors at the final stages of osteoblast differentiation
(17, 18). Vitamin D3 enhancement of OC gene transcription
is accompanied by changes in genomic protein/DNA and protein/protein
interactions and further modifications in chromatin structure (10, 16,
17, 19). Hence, chromatin remodeling is intricately associated with
modulations in OC gene transcription in response to bone-related
physiological regulatory cues.
The remodeling of chromatin structure is mediated in part by enzymes
that topologically alter the interactions of DNA with histone octamers
or that covalently modify the core histone proteins H3 and H4 (20-24).
Many co-activators and co-repressors that interact with promoter-bound
transcription factors represent chromatin-modifying enzymes capable of
acetylating or deacetylating lysine residues in the N termini of
histones H3 and H4 (25-29). Therefore, we have assessed in this study
whether acetylation or deacetylation of histones H3 and H4 in the
regulatory regions of a bone-related mammalian gene is linked
mechanistically to steroid hormone-dependent modifications
in osteoblast-specific gene expression.
Steroid hormone-dependent transcriptional control of
bone-specific genes necessitates functional modifications in chromatin organization (4, 30). Understanding chromatin structure of the
osteocalcin gene is fundamental in characterizing the molecular and
genetic mechanisms of bone cell differentiation. We have previously shown that developmental modifications in the nucleosomal organization of the OC gene are functionally coupled to the establishment of a local
promoter architecture containing two nuclease hypersensitive sites
separated by a positioned nucleosome (17, 18). These sites span the
distal VD3 enhancer and the proximal basal promoter, and increased
nuclease hypersensitivity of both sites accompanies vitamin D
enhancement of OC gene transcription (17, 18, 31). In this study, we
have addressed the mechanisms by which vitamin D3 mediates
chromatin remodeling of the OC gene to promote steroid hormone
enhancement of OC gene transcription. The key results of this study are
that the OC gene promoter is associated with acetylated histones H3 and
H4, when transcriptionally active, and that the relative level of
histone H4 acetylation is increased during vitamin D3
enhancement of transcription.
 |
MATERIALS AND METHODS |
Cell Culture--
ROS 17/2.8 and ROS 24/1 osteosarcoma cells
(32) were plated at 0.5 × 106 cells per 100-mm dish
and grown in F-12 medium plus 5% fetal calf serum. Cells reached
confluence at approximately day 6. Cells were treated with
10
8 M 1,25-(OH)2D3 (a
gift from Dr. M. Uskokovic, Hoffmann-La Roche) in F-12 medium
containing 2% fetal calf serum, which was growth factor- and steroid
hormone-depleted using charcoal ("stripped serum"). Samples were
collected at the indicated times following 1,25-(OH)2D3 administration, and the medium of
each sample was collected for radioimmunoassay to measure osteocalcin levels.
Antibodies--
Chromatin immunoprecipitation (ChIP) assays were
performed with antibodies recognizing acetylated histones. The
anti-acetylated histone H4 antibody (Upstate Biotechnology (UBI), Lake
Placid, NY, catalog no. 06866) is a rabbit antiserum containing a
polyclonal IgG directed against a tetra-acetylated peptide
(AGG(K*)GG(K*)GMG(K*)VGA(K*)RHSC, where K* is
acetylated lysine) that spans the highly conserved residues 1-19 of
histone H4 (H4-Ac1, 2) (33). This antibody recognizes
multiple acetylated forms of histone H4. The anti-acetylated histone H3
antibody (UBI, catalog no. 06599) is a protein A-purified rabbit
polyclonal IgG that is directed against the diacetylated peptide
(ARTKQTAR(K*)STGG(K*)APRKQLC) spanning the highly conserved N-terminal
residues 1-20 of histone H3. It has been noted that phosphorylation of
Ser-10 decreases the affinity of this antibody for deacetylated histone
H3 (34). The antibody that recognizes hyperacetylated histone H4
(H4-Ac3,4) (UBI, catalog no. 06946) is a rabbit antiserum
containing a polyclonal IgG directed against a synthetic substrate
related to residues 2-19 of Tetrahymena histone H2A.
This antibody recognizes multiple acetylated forms of histone H4 and,
to a lesser degree, triacetylated histone H4 (35, 36).
Western Blot Analysis--
Whole cell lysates were prepared from
ROS17/2.8 and ROS 24/1 cells by washing monolayers in ice-cold PBS and
resuspending cells in SDS-lysis buffer (0.5% SDS, 50 mM
Tris-HCl, pH 8.0, and 1 mM dithiothreitol). Cell pellets
were boiled and the lysates subjected to SDS-PAGE in 18% (40:1)
polyacrylamide gels. Proteins were transferred to polyvinylidene
difluoride membranes using a semi-dry electroblotter. After transfer,
nonspecific antibody binding sites were blocked with 5% nonfat milk
powder in phosphate-buffered saline (PBS, pH 7.4, 8.1 mM
Na2HPO4, 1.9 mM
NaH2PO4, 0.137 M NaCl, and 2.7 mM KCl) containing 0.1% Tween 20 (PBS-T buffer) for 1 h at 4 °C. Western blot analyses were performed with the
anti-acetylated H3 and H4 IgG antibodies (UBI, catalog no. 06599 and 06598, respectively), as well as with an antibody recognizing
phosphorylated histone H3. This antibody is a protein A-purified rabbit
polyclonal IgG directed against a peptide phosphorylated on serine
residue 10 and spanning amino acids 7-20 of histone H3 (37, 38).
Antibodies against HDAC1 and p300 (UBI, catalog no. 06-720 and 05-257)
and antibodies against CDK2, lamin B, and CPB (Santa Cruz
Biotechnology, Santa Cruz, CA, catalog no. SC-163, SC-6217, and
SC-1211) were obtained from the indicated suppliers. Primary antibodies
(as indicated in the figure legends) were added in PBS-T buffer at a
1:10,000 dilution, and the membrane was incubated overnight at 4 °C.
Bound antibody was detected using a secondary anti-rabbit immunoglobulin coupled to horse-radish peroxidase at a 1:10,000 dilution, and immunoreactive bands were visualized using the substrate 4-chloro-1-naphthol by autoradiography.
Chromatin Immunoprecipitation Assays--
ChIP assays were
performed with ROS 17/2.8 and ROS 24/1 osteosarcoma cells that were
grown with or without 1,25-(OH)2 D3. Prior to
harvest, cells were incubated for 10 min at room temperature in
incomplete F-12 medium containing 1% formaldehyde. This step stabilizes nucleosomes by the reversible cross-linking of histones with
DNA. Cells were washed and harvested in ice-cold PBS containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 1 mg/ml pepstatin A, 10 mg/ml TPCK, 4 mg/ml
bestatin, 17 mg/ml calpain, 1 mg/ml E64, and 10 mM sodium
butyrate). Cell pellets were resuspended in SDS lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris-Cl, pH 8.1, with
protease inhibitors as above) for 10 min on ice. Samples were sonicated
to reduce the DNA length to 0.1-0.6 kbp (median length = 0.4),
and cells were cooled on ice between pulses. Cellular debris was
removed by centrifugation for 10 min at 13,000 rpm at 4 °C in a
Beckman J-21 centrifuge with a J-20 rotor. The supernatant was diluted
10-fold in dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-Cl, pH 8.1, 16.7 mM NaCl) supplemented with a protease inhibitor mixture (1 mM phenylmethylsulfonyl fluoride, 1 mM
leupeptin, 1 mg/ml pepstatin A, 10 mg/ml TPCK, 4 mg/ml bestatin, 17 mg/ml calpain, and 1 mg/ml E64). Protein concentrations were determined
using Coomassie protein assay reagent (Pierce). The chromatin solution
was distributed into multiple 1-ml aliquots that were used as the
starting material for all subsequent steps.
DNA-coated protein A/G-agarose was prepared by incubating 500 µl of
beads with dilution buffer containing 10 mg/ml sonicated salmon sperm
DNA for 1 h at 4 °C with agitation. Excess DNA was removed by
centrifugation for 2 min at 3,000 rpm in an Eppendorf microcentrifuge at 4 °C followed by four sequential washes of the beads with dilution buffer. Prior to chromatin
immunoprecipitations, the 1-ml chromatin aliquots were pre-cleared with
100 µl of a 25% (v/v) suspension of DNA-coated protein A/G-agarose
in the absence of antibody. The supernatant was recovered following
brief centrifugation at 3,000 rpm in the Eppendorf microcentrifuge and was used directly for immunoprecipitation experiments with a 1:200 dilution of the acetylated histone H3 or H4 antibodies described above.
A nonspecific antibody against the unrelated hemagglutinin epitope tag
was used as a negative control. Chromatin immunoreactions were allowed
to proceed overnight at 4 °C on a rotating wheel. Immune complexes
were mixed with 100 µl of a 25% precoated protein A/G-agarose
suspension followed by incubation for 1 h at 4 °C while
rotating. Beads were collected by centrifugation at 3,000 rpm for 2 min
at 4 °C. The supernatant of this step in the procedure is
designated the "unbound DNA fraction." The bead pellets were sequentially washed with 1 ml each of the following buffers: low salt
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl, pH 8.1, 150 mM NaCl), high salt
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl, pH 8.1, 500 mM NaCl), and LiCl wash
buffer (0.25 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, and 10 mM Tris-Cl, pH
8.1). The beads were then washed twice using 1 ml of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
The immunocomplexes were eluted by adding a 250-µl aliquot of a
freshly prepared solution of 1% SDS, 0.1 M
NaHCO3. The sample was briefly vortexed and incubated at
room temperature for 15 min with rotation. Following recovery of the
supernatant by microcentrifugation, the beads were washed with a second
aliquot, and the resulting supernatant was carefully pooled with the
first aliquot. Samples were sequentially digested with RNase A
(10 mg/ml) at 37 °C for 1 h and proteinase K (20 mg/ml) at
42 °C for 2 h to remove RNA and protein. The cross-linking
reaction was reversed by overnight incubation of the sample at
68 °C, and the DNA was recovered by phenol/chloroform extractions.
The DNA was precipitated with two volumes of ethanol using 20 mg/ml
glycogen as carrier. Each DNA pellet was dissolved in 30 µl of TE
buffer (designated the "bound DNA fraction"). An aliquot (3 µl)
of each DNA fraction was used for quantitative PCR to detect the
presence of specific DNA segments.
For each immunoprecipitation, an aliquot of the starting material was
digested with RNase A (10 mg/ml) and proteinase K (20 mg/ml) and
incubated overnight at 68 °C to reverse the formaldehyde cross-links. The DNA was extracted with phenol/chloroform,
ethanol-precipitated with 20 mg/ml glycogen, and finally dissolved in
100 µl of TE buffer (designated the "input DNA fraction").
Aliquots (1 µl) of this input DNA preparation were used for
quantitative PCR and Southern blot analysis.
Polymerase Chain Reaction--
PCR primer pairs were generated
to detect DNA segments located between nt
1377 and +466 of the rat
osteocalcin promoter (nt +1 is the mRNA cap-site) (Fig.
1a). We also designed PCR primers to detect a rat histone H4
(His4) gene coding region (Fig. 1b) to facilitate the
normalization of PCR signals obtained with OC-derived primers. Each PCR
reaction was performed with a 10% aliquot (3 µl) of the bound DNA
fraction from the ChIP assay or a 1% aliquot (1 µl) of the unbound
fraction. DNA was amplified with each primer at 0.4 mM,
each dNTP at 0.18 mM, and 0.5 µl of Taq
polymerase (5 u/µl) in 1× buffer provided by the manufacturer (Roche
Molecular Biochemicals) in a PerkinElmer 480 thermocycler. The
PCR thermocycler was programmed as follows: preincubation at 95 °C
for 1 min, 26 cycles of 30 s denaturation at 95 °C, 30 s
at the optimal annealing temperature for each primer pair (see Fig.
1c), and 30 s at 72 °C, with one final incubation at
72 °C for 5 min. The PCR products were separated in 2.0% agarose
gels containing 0.5 µg/ml ethidium bromide. DNA bands were visualized
using ultraviolet light and recorded as tagged image file format (TIF)
files using a high resolution charge-coupled device (CCD) camera linked
to an AlphaImager gel documentation system (Alpha Innotech, San
Leandro, CA). TIF files of ethidium bromide-stained gels were subjected
to densitometric analysis by Image J, developed by Wayne Rasband
(National Institutes of Health, Bethesda, MD). Values were
imported into Microsoft Excel for numerical analysis and data plotting.
 |
RESULTS |
The OC Promoter Is Associated with Acetylated Histones H3 and H4 in
Osseous Cells Actively Expressing the OC Gene--
The osteocalcin
gene is constitutively expressed in ROS 17/2.8 rat osteosarcoma cells,
and its promoter displays an active chromatin conformation reflected by
the presence of two DNase I hypersensitive sites (17, 18). To assess
whether acetylated histones are associated with the OC gene when it is
transcriptionally active, we performed ChIP assays with antibodies
recognizing mono- and diacetylated histone H3 (H3-Ac) and multiple
acetylated forms of histone H4 (H4-Ac1,2 and
H4-Ac3,4). These antibodies were used in whole cell lysates
to precipitate sonicated chromatin that was obtained following
formaldehyde cross-linking of DNA to histones in vivo. DNA
fragments that co-precipitated with acetylated histones were purified
upon reversal of histone/DNA cross-links and used as the template for
PCR reactions with gene-specific primers (Fig. 1). We adjusted the number of PCR cycles
to remain within the linear range of PCR amplification. The
resulting DNA products were resolved by agarose electrophoresis,
visualized by ethidium bromide staining, and quantitated by digital
image analysis (Fig. 2). Chromatin
immunoprecipitates were analyzed with a series of PCR primers covering
the OC locus between -1.4 and +0.5 kb relative to the mRNA
cap-site (Fig. 1, a and c). In each experiment,
the specificity of the PCR procedure was assessed by appropriate
positive and negative control reactions in which either specific
primers or templates were omitted. Furthermore, the authenticity of the PCR products was validated by Southern blot analysis with probes spanning the OC gene (data not shown). For comparison, we also tested
PCR primers spanning the coding region of a cell growth regulated rat
histone H4 (His4) gene (Fig. 1b), which is
expressed in a broad range of proliferating cells and tissues (39).

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
Primers used for PCR-mediated detection of
DNA regions containing acetylated chromatin. The PCR primer
pairs used for the detection of DNA segments of the genes for
osteocalcin (a) and histone H4 (b) in chromatin
immunoprecipitation assays are illustrated schematically. Panel
a shows the PCR primer pairs above a diagram of the OC
locus, which depicts (left to right, B1/B2
repetitive sequences, gene regulatory elements (e.g.
Runx2/Cbfa1 binding sites A, B, and C;
VDRE), and the exons (X) and introns
(I) of the OC mRNA coding sequences.
Underneath the diagram is a summary of chromatin data from
previous studies, including the location of two DNase I hypersensitive
sites and a positioned nucleosome (18). Panel c shows the
oligonucleotide sequences of the primers indicated in a and
b. The numbers in the leftmost column
refer to the most 5' nucleotide and span either the coding strand
(Forward) or noncoding strand of the OC gene
(Reverse). The columns to the right provide a
conceptual description, as well as the melting temperatures
(Tm) and the length of the PCR products from the osteocalcin
and histone H4 genes. The His4 primer pair +52/+272 was used
with OC primer pairs 773/ 433 and 459/ 118; 18/+276 with OC
1377/ 1176, 198/ 28, and +289/+466; and 70/+223 with OC
1047/ 827 in all PCR reactions.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 2.
Association of acetylated histones H3 and H4
with the promoter of the osteocalcin gene in ROS 17/2.8
osteosarcoma cells that actively express osteocalcin.
Immunoprecipitation assays were performed with
formaldehyde-cross-linked chromatin isolated from ROS 17/2.8 cells and
antibodies against acetylated histones H3 and H4. Panel a
shows ethidium bromide-stained agarose gels of PCR products obtained
with OC primer pairs 773/ 433 and 459/ 118 in chromatin
immunoprecipitates with the indicated antibodies (H3-Ac,
H4-Ac1,2, H4-Ac3,4,
NS). The arrows on the right indicate
the relative locations of the PCR reaction products. The
His4 gene signals (primer pairs +52/+272) observed in the
left and right lanes for each panel
should be equal, and any differences in intensities reflect
experimental variation. Panel b shows the quantitation
of signal intensities of the PCR products from three separate
experiments that were digitally recorded with a CCD camera and
quantitated using ImageJ, version 1.22d (developed by Wayne Rasband,
National Institutes of Health). For each lane, the values were
expressed as the ratio of the OC signal versus the His4
signal (which represents a parallel parameter for comparison) and
plotted for each antibody. Values for the nonspecific antibody in
panel a (NS) are not included in the graph.
Panels c and d are the same as Panels
a and b, respectively, except that different
primer pairs were used and the size of the PCR product for the His4
primer pair is larger than that for the OC primer pairs.
|
|
We first analyzed the acetylation status of histones within the region
of the OC promoter that contains the distal nuclease hypersensitive
site and the vitamin D enhancer (nt
773/
433), as well as the
nucleosomal region between the proximal and distal promoters (nt
459/
118) (Fig. 2a). The results show that all three acetylated histone antibodies (H3-Ac, H4-Ac1,2, and
H4-Ac3,4) precipitate fragments from the OC gene and also
the His4 gene. However, no signal was detected in
precipitates obtained with an antibody recognizing the unrelated
hemagglutinin epitope (panel NS, Fig. 2a), which
provides a negative control for our chromatin immunoprecipitations.
These results indicate that different acetylated forms of histones H3
and H4 are specifically associated with nucleosomes in the vicinity of
the transcriptionally active OC and His4 genes.
The PCR signals for the His4 gene are relatively uniform for
the three acetylated histone antibodies (Fig. 2a). Thus, we
normalized the values for the OC primers with those for the His4
primers and expressed our results as OC/His4 ratios (Fig.
2b). We find that the OC/His4 ratios for the OC
773/
433
and OC
459/
118 primer pairs are lowest for the H3-Ac antibody
(OC/His4 ratios of 0.2 to 0.4) and ~2-fold higher for the
H4-Ac1,2 and H4-Ac3,4 antibodies (OC/His4
ratios of 0.4 to 0.8). These results indicate quantitative differences
in the relative representation of acetylated histones H4 and H3 at the
OC gene as compared with the His4 locus. These differences
suggest that the OC gene promoter is preferentially associated with
acetylated histone H4 compared with the His4 gene.
Differential Association of Acetylated Histones H3 and H4 across
the OC Locus When the OC Gene Is Transcriptionally Active--
To
understand the relative distribution of acetylated histones across the
OC gene promoter, we performed additional PCR experiments using primers
upstream from the vitamin D-dependent enhancer region and
downstream at the proximal promoter and OC coding region (Fig. 2c). We analyzed immunoprecipitates with the H3-Ac,
H4-Ac1,2, and H4-Ac3,4 antibodies using
chromatin isolated from ROS 17/2.8 cells. The results indicate that the
OC promoter regions
1047/
827 and
198/
28 contain on the average
1.5-3-fold higher levels of acetylated histones H3 and H4 than the OC
segments in the far distal promoter (
1377/
1176) and the OC coding
sequence (+289/+466) (Fig. 2d). Thus the relative level of
acetylation of histones H3 and H4 gradually declines in chromatin
upstream from
1.0 kb and downstream from the mRNA cap-site. The
levels of acetylated forms of H4 are significantly higher than those
for acetylated histone H3 throughout the OC locus. The level of histone
H4 acetylation is highest in the
1047/
827 and
198/
28 regions
and is reduced by 1.5-2-fold in the
1377/
1176 and +289/+466
regions (Fig. 2, c and d). These data indicate
that there are transitions in the acetylation status of histones H3 and
H4 that correspond with the regulatory boundaries of the OC gene
promoter. Our findings further indicate that the promoter region from
approximately
1.0 to 0.0 kb, which encompasses the principal
regulatory elements and two major nuclease hypersensitive domains of
the OC promoter, contains relatively high levels of acetylated histones
H3 and H4.
Absence of Acetylated Histones H4 and H3 in ROS
24/1 Osteosarcoma Cells That Do Not Express Mature
Bone Phenotypic Markers--
To gain insight into the acetylation
status of histones at the OC locus when the gene is transcriptionally
inactive, we carried out ChIP assays with histone-DNA complexes
isolated from both ROS 17/2.8 and ROS 24/1 osteosarcoma cells. ROS 24/1
cells do not express markers of the mature bone phenotype including
osteocalcin (40-42). In addition, the OC promoter adopts a closed and
transcriptionally silent chromatin conformation in ROS24/1 cells that
is reflected by absence of DNase I hypersensitive sites (17). The data
in Fig. 3 demonstrate that chromatin
immunoprecipitates from ROS 24/1 obtained with the H3-Ac,
H4-Ac1,2, and H4-Ac3,4 antibodies all contain
DNA fragments derived from the His4 gene. Strikingly, none
of these antibodies precipitates significant amounts of either the OC
773/
443 or OC
459/
118 fragments (Fig. 3a). For
example, the OC/His4 ratios for the OC
773/
443 and OC
459/
118
regions are 10-20-fold lower in ROS 24/1 cells than in ROS 17/2.8
cells for all three antibodies (Fig. 3b). Quantitation of
ChIP assay results from three independent experiments reveals that the
levels of histone H3 and H4 acetylation are reduced in ROS 24/1 as
compared with ROS17/2.8 cells, across the entire locus (Fig. 3,
c and d). The differences in the acetylation
status of the OC gene in ROS 24/1 cells where the OC gene is not
expressed and in ROS 17/2.8 cells where the OC gene is transcribed,
suggest that acetylation of histones H3 and H4 is functionally coupled
to bone tissue-specific transcriptional activation of OC gene
expression and an open chromatin conformation.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 3.
Reduced levels of histones H3 and H4
acetylation at the OC locus in fibroblastic ROS 24/1 cells that do not
express the OC gene. Chromatin immunoprecipitation assays are
presented as described in Fig. 2 using samples isolated from ROS 17/2.8
and ROS 24/1 cells as indicated. Panels a and c
show ethidium bromide-stained agarose gels of PCR products obtained
with the indicated OC primer pairs and antibodies. The
arrows on the right indicate the relative
locations of the PCR reaction products. The OC signal is above the
His4 signal in a and below the His4 signal in
c. Panels b and d show quantitations
of the experiments presented in a and c as
described in Fig. 2. The ratio of the OC versus the His4
signals observed for each of the three acetylated histone antibodies
(i.e. H3-Ac, H4-Ac1,2 and
H4-Ac3,4) was plotted for each region of the OC
promoter to permit direct comparison of the results for ROS17/2.8 and
ROS 24/1 cells.
|
|
Histone Acetylation at the OC Promoter Is Selectively Increased
following Vitamin D3 Enhancement of OC Gene Transcription
in ROS17/2.8 Cells--
Steroid hormone dependent
up-regulation of OC gene expression is mediated at least in part by
transcriptional mechanisms and occurs concomitant with structural
changes in chromatin organization (17, 43). Administration of vitamin
D3 strongly enhances OC gene expression in ROS 17/2.8 cells
but not in ROS24/1 cells, which lack a functional vitamin D receptor
(44). In our experiments, the enhancement of OC gene expression was
evident at 2.5 h after VD3 treatment and increased until 24 h
after treatment (data not shown), in agreement with our previous
analysis of transcription by nuclear run-on assays (10). In contrast,
the levels of glyceraldehyde-3-phosphate dehydrogenase and histone H4
mRNAs remained relatively constant or decreased modestly throughout
the time course (data not shown). These data provide the basis for
assessing whether VD3-dependent modulation of OC gene
expression involves modifications in histone acetylation. Western blot
analysis reveals that the levels of acetylated histones H4 and H3 are
increased modestly within 45 min following VD3 induction but do not
change significantly thereafter (Fig. 4
and data not shown). Interestingly, the levels of phosphorylated histone H3 are rapidly increased by 45 min after VD3 addition. Consistent with large pre-existing pools of histones packaged as
nucleosomes, total cellular levels of histone proteins remain similar
based on Coomassie Blue staining of SDS gels (Fig. 4). Major changes
are also not apparent in the levels of CDK2 and lamin B or in the
levels of the histone acetyltransferases CBP (CREB-binding protein) and
P/CAF (p300/CBP-associated factor), or the histone deacetylase HDAC1
(Fig. 4). Therefore, we favor the interpretation that the vitamin
D-dependent, rapid elevation of acetylated and
phosphorylated histone H3 is not due to increased H3 protein levels but
reflects increased post-translational modifications. Changes in OC gene
expression at the mRNA level (data not shown) or by nuclear run-on
analysis (10, 17) are not apparent until later during the time course
(>2.5 h). Hence, these global histone modifications do not temporally
correlate with, and thus cannot mechanistically account for, the
gene-specific enhancement of osteocalcin gene expression by VD3.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 4.
Increased histones H4 and H3 acetylation
following vitamin D treatment. Western blot analyses were
performed with cell lysates from vitamin D-treated ROS 17/2.8 cells and
antibodies against acetylated H4 and H3 histones (H4-Ac and
H3-Ac, respectively), phosphorylated H3 (H3-P),
lamin B (control for protein loading), P/CAF, CBP, HDAC1, or CDK2.
Whole cell lysates were prepared at the indicated times after vitamin D
treatment. The left lane shows purified histone proteins
from butyrate-treated ROS 17/2.8 cells. The top panel shows
Coomassie Blue staining of the gel and reveals that total cellular
levels of histone proteins are similar following vitamin D
treatment.
|
|
We therefore investigated whether VD3-dependent enhancement
of OC gene transcription is accompanied by modifications in the acetylation status of histones H3 and H4 associated specifically with
the OC gene locus (Figs. 5 and 6). ROS
17/2.8 cells were cultured for 12 h in vitamin
D3-depleted medium, and vitamin
D3-dependent effects on histone acetylation
were monitored by ChIP assays in cells harvested at 45 min and 2.5 and
24 h following the administration of 10 nM
(1,25)-dihydroxyvitamin D3.
We found that acetylation of histone H3 or H4 proteins associated with
the
773/
433 and
459/
118 regions of the OC gene is not
significantly enhanced after short term treatment (i.e. 45 min) with vitamin D3 (Fig. 5a, top). However, the
levels of acetylated histone H4 were modestly up-regulated at 2.5 h after treatment in the
459/
118 segment of the OC gene promoter
(Fig. 5a, center). Histone H4 acetylation was
further enhanced by 24 h after vitamin D3 treatment
(Fig. 5a, bottom). The levels of acetylated
histone H3 at the
773/
433 and
459/
118 regions of the OC gene
remained relatively constant during the first 2.5 h but were
modestly increased by 24 h (Fig. 5a). In contrast, the
levels of acetylated histones H3 and H4 in the His4 gene
remained constant or were down-regulated following vitamin
D3 administration. Our results are expressed quantitatively and summarized in Fig. 5c. We conclude that vitamin
D3 enhancement of OC gene transcription in ROS 17/2.8 cells
is accompanied by a selective increase in acetylation of histone H4
and, to a lesser extent, by acetylation of histone H3 associated with
the
773/
433 and
459/
118 regions of the OC gene.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 5.
Selective increase in histone H3 and H4
acetylation near the VDRE region of the osteocalcin gene following
vitamin D enhancement of osteocalcin gene expression. Chromatin
immunoprecipitation assays were performed with antibodies against
acetylated histones (see legend to Fig. 2). Chromatin was isolated from
ROS 17/2.8 cells (a) or ROS 24/1 cells (b)
following incubation of cells with (d) or without
(c) treatment with vitamin D3 for 45 min or 2.5 or 24 h as indicated. The ethidium bromide-stained agarose gels
show PCR products obtained with OC primer pairs 773/ 433 or
459/ 118 or His4 primers +52/+272. The left lane
in each gel represents a 100-bp repeat DNA marker, and the
arrowheads indicate the relative locations of the PCR
products. Panel c shows the quantitation of signal
intensities of the PCR products as described in Fig. 2. Values were
first expressed as the ratio of the OC signal versus the
His4 signal (OC/His4 ratio), and the quotient of the OC/His4 ratio in
vitamin D-treated cells versus untreated control cells was
plotted as the fold response to vitamin D.
|
|

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 6.
Enhancement of histones H3 and H4 acetylation
in response to vitamin D in VDRE proximal regions of the osteocalcin
gene. Chromatin immunoprecipitation assays are presented as
described in Fig. 6 using samples isolated from ROS 17/2.8 or from ROS
24/1 cells incubated for 24 h in the absence (C) or
presence (D) of vitamin D. The figure shows multiple
ethidium bromide-stained gels with PCR products from precipitates
analyzed with different OC primer pairs as indicated. The
arrowheads on the right mark the relative
locations of the PCR products.
|
|
Analysis of chromatin from ROS 24/1 cells treated with the same
concentration of VD3 and for the same duration as ROS17/2.8 cells (Fig.
5b) reveals that VD3 does not induce acetylation of either
histone H3 or histone H4 proteins associated with the OC gene. These
data demonstrate that steroid hormone-dependent
modifications in histone acetylation at the OC gene promoter are absent
in ROS 24/1.
We also analyzed vitamin D effects on histone acetylation of OC gene
segments upstream from
773 and downstream from
198 (Fig. 6 and data
not shown). The data reveal that the proximal promoter (
198/
28) and
coding region (+289/+466) each exhibit major changes in histone H3 and
H4 acetylation at 24 h after vitamin D3 treatment of
ROS 17/2.8 cells (Fig. 6a). Similar to the results obtained
for the
773/
433 and
459/
118 regions of the OC gene (Fig.
5a), changes in histone acetylation status in the
198/
28 and +289/+466 regions are already apparent but less dramatic at 2.5 h (data not shown). In contrast, the
1047/
827 region does not exhibit major changes in histone acetylation at either 2.5 or
24 h after vitamin D3 treatment (Fig. 6a
and data not shown). Furthermore, similar to results presented in Fig.
5b, no modifications in histone acetylation at the
1047/
827,
198/
28 or +289/+466 regions were observed at any time
after vitamin D3 treatment of ROS 24/1 cells (Fig.
6b and data not shown). Taken together, our findings
indicate that increased acetylation of the OC promoter in response to
vitamin D3 does not occur upstream from
827 but is
evident at the VDRE (
773/
433) and downstream at the proximal promoter (
198/
28) and coding (+289/+466) segments of the OC gene,
as well as in the segment (
459/
118) spanning the positioned nucleosome between the proximal and distal regulatory regions. Therefore, our results establish that there are selective changes in
histone acetylation of the OC gene that accompany and may be mechanistically linked to chromatin remodeling and vitamin
D3-dependent enhancement of transcription.
 |
DISCUSSION |
In this study, we experimentally addressed the functional coupling
between histone acetylation and osteocalcin gene transcription in
osseous cells in the presence or absence of vitamin D3
using chromatin immunoprecipitation assays. We find that the OC gene promoter is associated with acetylated histones H3 and H4 when transcriptionally active and that acetylation of histone H4 is increased in response to vitamin D3. Furthermore, these
results together with previous data from our laboratory (17, 18, 31) indicate that enhancement of OC gene transcription is mediated by
specific changes in higher order chromatin structure and modifications in the acetylation status of histones H3 and H4.
Our previous studies demonstrated that cells expressing the
bone-specific OC gene exhibit two DNase I hypersensitive sites spanning
the proximal (nt
170 to
70) and distal (nt
600 to
400) promoter
regions and a nucleosome positioned between these hypersensitive sites
(17, 18). In other studies, we found that treatment of ROS 17/2.8 cells
with the histone deacetylase inhibitor sodium butyrate blocks vitamin D
stimulation of OC transcription (31). This inhibition is accompanied by
loss of the distal DNase I hypersensitive site spanning the VDRE
region. These data indicate that perturbation of the reversible
acetylation and deacetylation of the N-terminal tails of histones
affects the chromatin structure and transcriptional activity of the OC
promoter. In the current study, by analyzing multiple segments spanning
the OC locus, we have shown first that the highest levels of acetylated
histones correspond to regions containing principal OC gene regulatory elements and, second, that vitamin D treatment selectively increases acetylation of histone H4 proximal to the vitamin D enhancer region.
The association of histone acetylation with transactivation and
deacetylation with repression was first suggested in 1964 by Allfrey
et al. (45). Many studies subsequently supported the
correlation between histone acetylation and active gene transcription (46, 47). In the chicken
-globin locus, hyperacetylated
histones are present when the locus is transcriptionally active (48). In the
-globin promoter, a very specific and directed acetylation of
histone H3 at a TATA-proximal nucleosome occurs during transcriptional activation, whereas acetylation of H4 appears to be more widespread and
involves two nucleosomes spanning almost 400 bp of the
-globin 5'
flanking sequence (49). Analysis of the histone acetylation status of X
chromosomal genes showed that the promoter regions of actively
expressed genes (e.g. OCRL, PGK1, and
XIST) are hyperacetylated regardless of whether they are
located on the inactive (Xi) or active (Xa) chromosome. In contrast,
the promoters of silent genes (e.g. ODS, XPCT,
and NDP) on the Xi chromosome are associated with
hypoacetylated histone H4 (50). Our findings demonstrate that histone
H3 and H4 acetylation at the bone-tissue specific OC locus occurs only
when the gene is transcriptionally active.
Several hormone-responsive genes have been shown to undergo changes in
histone acetylation upon ligand treatment. Four estrogen-responsive genes (pS2, EB1, c-myc, and
CTD) were shown to exhibit preferential acetylation of H4
versus H3 in the promoter regions following estrogen
treatment (51). The pS2 and CTD genes initially
showed low levels of histone H4 acetylation, which increased in
response to estradiol and reached maximal levels at 60 min in a
receptor-dependent manner. These results and our data,
which demonstrate vitamin D-dependent modifications in
histone acetylation at the OC gene, suggest that histone H4 acetylation
is functionally coupled with steroid hormone-dependent
transcriptional activation of cellular genes.
There are several distinct genes involved in metabolic regulation or
cell cycle control for which acetylation of histone H3, but not H4,
correlates with increased transcription. Acetylated histone H3, but not
H4, is associated with the promoter region of the StAR
(steroidogenic acute regulatory
protein) gene when it is transcriptionally active (52). Acetylated
histone H3, but not H4, increased in chromatin at the low density
lipoprotein receptor and hydroxymethylglutaryl-CoA reductase
promoters (53). Selective hyperacetylation of H3 is associated with
cell cycle regulation of the p21WAF1 (54) and histone H4
genes.2 We conclude that
differential acetylation of histones H3 and H4 at gene promoters is
involved in selective changes in chromatin in response to physiological signals.
The variety and dynamics of histone protein acetylation observed at the
promoters of different genes suggest that acetylation of histones
functions in transcriptional regulation through highly intricate
mechanisms. One mechanism may involve electrostatic repulsion between
acetylated histones and DNA. More recently, it has become apparent that
acetylation modulates interactions among adjacent nucleosomes (21, 22,
24, 55). In addition, a histone code of post-translational
modifications may direct transcription factors and co-factors to the
promoter (20, 56, 57). Further, the association of SWI/SNF chromatin
remodeling complexes with chromatin is stabilized by histone
acetylation (23, 58). Accumulating evidence suggests that acetylation of the N-terminal tails of H3 and H4 may be a principal regulator of
transcription factor access to nucleosomal DNA and the establishment of
transcription initiation complexes at gene promoters (49, 59).
In summary, our data support the concept that bone tissue-specific
activation of the osteocalcin gene requires acetylation of histones H3
and H4 to establish an open chromatin conformation and basal levels of
transcription. Subsequent vitamin D-dependent enhancement
of OC gene transcription involves acetylation of histone H4 and
increased accessibility of proximal and distal promoter regions. These
findings provide the basis for future studies on the sequential order
of events required for chromatin remodeling that occurs during normal
osteoblast differentiation.
 |
ACKNOWLEDGEMENTS |
We thank Judy Rask for preparation of this
manuscript and Hayk Hovhannisyan and Soraya Gutierrez for helpful discussions.
 |
FOOTNOTES |
*
This study was supported by National Institutes of Health
Grants AR45689, DE12528, AR39588, TW00990, and DK52320.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Cell
Biology, 55 Lake Ave. North, University of Massachusetts Medical School, Worcester, MA 01655. Tel.: 508-856-5625; Fax: 508-856-6800; E-mail: janet.stein@umassmed.edu.
Published, JBC Papers in Press, March 13, 2002, DOI 10.1074/jbc.M112440200
2
B. Cho, H. Hovhannisyan, M. Montecino,
J. B. Lian, A. J. van Wijnen, J. L. Stein, and G. S. Stein, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
VDR, vitamin
D3 receptor;
VDRE, vitamin D3 response element;
VD3, vitamin D3;
OC, osteocalcin;
ChIP, chromatin
immunoprecipitation;
PBS, phosphate-buffered saline;
TPCK, L-1-tosylamido-2-phenylethyl chloromethyl ketone;
H4-Ac, acetylated histone H4;
H3-Ac, acetylated histone H3;
nt, nucleotide(s);
CBP, CREB-binding protein;
CCD camera, charge-coupled device
camera.
 |
REFERENCES |
| 1.
|
Stein, G. S.,
Lian, J. B.,
Stein, J. L.,
van Wijnen, A. J.,
and Montecino, M.
(1996)
Physiol. Rev.
76,
593-629[Abstract/Free Full Text]
|
| 2.
|
Aubin, J. E.
(1998)
J. Cell. Biochem. Suppl.
30-31,
73-82[Medline]
[Order article via Infotrieve]
|
| 3.
|
Lian, J. B.,
Stein, G. S.,
Stein, J. L.,
and van Wijnen, A. J.
(1999)
in
Vitamins and Hormones
(Litwack, G., ed)
, pp. 443-509, Academic Press, San Diego
|
| 4.
|
Rachez, C.,
and Freedman, L. P.
(2000)
Gene
246,
9-21[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Tsai, M.-J.,
and O'Malley, B. W.
(1994)
Annu. Rev. Biochem.
63,
451-486[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
MacDonald, P. N.,
Dowd, D. R.,
Nakajima, S.,
Galligan, M. A.,
Reeder, M. C.,
Haussler, C. A.,
Ozato, K.,
and Haussler, M. R.
(1993)
Mol. Cell. Biol.
13,
5907-5917[Abstract/Free Full Text]
|
| 7.
|
Morrison, N. A.,
Shine, J.,
Fragonas, J. C.,
Verkest, V.,
McMenemy, L.,
and Eisman, J. A.
(1989)
Science
246,
1158-1161[Abstract/Free Full Text]
|
| 8.
|
Demay, M. B.,
Gerardi, J. M.,
DeLuca, H. F.,
and Kronenberg, H. M.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
369-373[Abstract/Free Full Text]
|
| 9.
|
Markose, E. R.,
Stein, J. L.,
Stein, G. S.,
and Lian, J. B.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
1701-1705[Abstract/Free Full Text]
|
| 10.
|
Breen, E. C.,
van Wijnen, A. J.,
Lian, J. B.,
Stein, G. S.,
and Stein, J. L.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12902-12906[Abstract/Free Full Text]
|
| 11.
|
Cheskis, B.,
and Freedman, L. P.
(1994)
Mol. Cell. Biol.
14,
3329-3338[Abstract/Free Full Text]
|
| 12.
|
Kliewer, S. A.,
Umesono, K.,
Mangelsdorf, D. J.,
and Evans, R. M.
(1992)
Nature
355,
446-449[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Staal, A.,
van Wijnen, A. J.,
Birkenhäger, J. C.,
Pols, H. A. P.,
Prahl, J.,
DeLuca, H.,
Gaub, M.-P.,
Lian, J. B.,
Stein, G. S.,
van Leeuwen, J. P. T. M.,
and Stein, J. L.
(1996)
Mol. Endocrinol.
10,
1444-1456[Abstract]
|
| 14.
|
Owen, T. A.,
Bortell, R.,
Shalhoub, V.,
Heinrichs, A.,
Stein, J. L.,
Stein, G. S.,
and Lian, J. B.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1503-1507[Abstract/Free Full Text]
|
| 15.
|
Owen, T. A.,
Aronow, M.,
Shalhoub, V.,
Barone, L. M.,
Wilming, L.,
Tassinari, M. S.,
Kennedy, M. B.,
Pockwinse, S.,
Lian, J. B.,
and Stein, G. S.
(1990)
J. Cell. Physiol.
143,
420-430[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Javed, A.,
Gutierrez, S.,
Montecino, M.,
van Wijnen, A. J.,
Stein, J. L.,
Stein, G. S.,
and Lian, J. B.
(1999)
Mol. Cell. Biol.
19,
7491-7500[Abstract/Free Full Text]
|
| 17.
|
Montecino, M.,
Pockwinse, S.,
Lian, J.,
Stein, G.,
and Stein, J.
(1994)
Biochemistry
33,
348-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Montecino, M.,
Lian, J.,
Stein, G.,
and Stein, J.
(1996)
Biochemistry
35,
5093-5102[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Guo, B.,
Aslam, F.,
van Wijnen, A. J.,
Roberts, S. G. E.,
Frenkel, B.,
Green, M.,
DeLuca, H.,
Lian, J. B.,
Stein, G. S.,
and Stein, J. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
121-126[Abstract/Free Full Text]
|
| 20.
|
Jenuwein, T.,
and Allis, C. D.
(2001)
Science
293,
1074-1080[Abstract/Free Full Text]
|
| 21.
|
Urnov, F. D.,
and Wolffe, A. P.
(2001)
Oncogene
20,
2991-3006[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Aalfs, J. D.,
and Kingston, R. E.
(2000)
Trends Biochem. Sci.
25,
548-555[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Peterson, C. L.,
and Workman, J. L.
(2000)
Curr. Opin. Genet. Dev.
10,
187-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Spencer, V. A.,
and Davie, J. R.
(1999)
Gene
240,
1-12[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Bannister, A. J.,
and Kouzarides, T.
(1996)
Nature
384,
641-643[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Ogryzko, V. V.,
Schiltz, R. L.,
Russanova, V.,
Howard, B. H.,
and Nakatani, Y.
(1996)
Cell
87,
953-959[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Mizzen, C. A.,
Yang, X. J.,
Kokubo, T.,
Brownell, J. E.,
Bannister, A. J.,
Owen-Hughes, T.,
Workman, J.,
Wang, L.,
Berger, S. L.,
Kouzarides, T.,
Nakatani, Y.,
and Allis, C. D.
(1996)
Cell
87,
1261-1270[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Taunton, J.,
Hassig, C. A.,
and Schreiber, S. L.
(1996)
Science
272,
408-411[Abstract]
|
| 29.
|
Emiliani, S.,
Fischle, W.,
Van Lint, C., Al,
Abed, Y.,
and Verdin, E.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2795-2800[Abstract/Free Full Text]
|
| 30.
|
Lian, J. B.,
Stein, G. S.,
Stein, J. L.,
and van Wijnen, A. J.
(1998)
Biochem. Soc. Trans.
26,
14-21[Medline]
[Order article via Infotrieve]
|
| 31.
|
Montecino, M.,
Frenkel, B.,
van Wijnen, A. J.,
Lian, J. B.,
Stein, G. S.,
and Stein, J. L.
(1999)
Biochemistry
38,
1338-1345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Majeska, R. J.,
Rodan, S. B.,
and Rodan, G. A.
(1980)
Endocrinology
107,
1494-1503[Abstract]
|
| 33.
|
Alberts, A. S.,
Geneste, O.,
and Treisman, R.
(1998)
Cell
92,
475-487[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Braunstein, M.,
Sobel, R. E.,
Allis, C. D.,
Turner, B. M.,
and Broach, J. R.
(1996)
Mol. Cell. Biol.
16,
4349-4356[Abstract]
|
| 35.
|
Lin, R.,
Leone, J. W.,
Cook, R. G.,
and Allis, C. D.
(1989)
J. Cell Biol.
108,
1577-1588[Abstract/Free Full Text]
|
| 36.
|
Perry, C. A.,
Allis, C. D.,
and Annunziato, A. T.
(1993)
Biochemistry
32,
13615-13623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Hendzel, M. J.,
Wei, Y.,
Mancini, M. A.,
Van Hooser, A.,
Ranalli, T.,
Brinkley, B. R.,
Bazett-Jones, D. P.,
and Allis, C. D.
(1997)
Chromosoma
106,
348-360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Wei, Y., Yu, L.,
Bowen, J.,
Gorovsky, M. A.,
and Allis, C. D.
(1999)
Cell
97,
99-109[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Wolfe, S. A.,
Anderson, J. V.,
Grimes, S. R.,
Stein, G. S.,
and Stein, J. S.
(1989)
Biochim. Biophys. Acta
1007,
140-150[Medline]
[Order article via Infotrieve]
|
| 40.
|
Rodan, S. B.,
Wesolowski, G.,
and Rodan, G. A.
(1986)
J. Bone Miner. Res.
1,
213-220[Medline]
[Order article via Infotrieve]
|
| 41.
|
Nagata, T.,
Gupta, V.,
Sorce, D.,
Kim, W. Y.,
Sali, A.,
Chait, B. T.,
Shigesada, K.,
Ito, Y.,
and Werner, M. H.
(1999)
Nat. Struct. Biol.
6,
615-619[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Demay, M. B.,
Roth, D. A.,
and Kronenberg, H. M.
(1989)
J. Biol. Chem.
264,
2279-2282[Abstract/Free Full Text]
|
| 43.
|
Owen, T. A.,
Aronow, M. S.,
Barone, L. M.,
Bettencourt, B.,
Stein, G. S.,
and Lian, J. B.
(1991)
Endocrinology
128,
1496-1504[Abstract]
|
| 44.
|
Baran, D. T.,
Sorensen, A. M.,
Shalhoub, V.,
Owen, T.,
Oberdorf, A.,
Stein, G.,
and Lian, J.
(1991)
J. Bone Miner. Res.
6,
1269-1275[Medline]
[Order article via Infotrieve]
|
| 45.
|
Allfrey, V. G.,
Faulkner, R.,
and Mirsky, A. E.
(1964)
Proc. Natl. Acad. Sci. U. S. A.
51,
786-794[Free Full Text]
|
| 46.
|
Grunstein, M.
(1997)
Nature
389,
349-352[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Wolffe, A. P.,
and Guschin, D.
(2000)
J. Struct. Biol.
129,
102-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Hebbes, T. R.,
Clayton, A. L.,
Thorne, A. W.,
and Crane-Robinson, C.
(1994)
EMBO J.
13,
1823-1830[Medline]
[Order article via Infotrieve]
|
| 49.
|
Gui, C. Y.,
and Dean, A.
(2001)
Mol. Cell. Biol.
21,
1155-1163[Abstract/Free Full Text]
|
| 50.
|
Gilbert, S. L.,
and Sharp, P. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
13825-13830[Abstract/Free Full Text]
|
| 51.
|
Chen, H.,
Lin, R. J.,
Xie, W.,
Wilpitz, D.,
and Evans, R. M.
(1999)
Cell
98,
675-686[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Christenson, L. K.,
Stouffer, R. L.,
and Strauss, J. F., III
(2001)
J. Biol. Chem.
276,
27392-27399[Abstract/Free Full Text]
|
| 53.
|
Bennett, M. K.,
and Osborne, T. F.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
6340-6344[Abstract/Free Full Text]
|
| 54.
|
Sambucetti, L. C.,
Fischer, D. D.,
Zabludoff, S.,
Kwon, P. O.,
Chamberlin, H.,
Trogani, N., Xu, H.,
and Cohen, D.
(1999)
J. Biol. Chem.
274,
34940-34947[Abstract/Free Full Text]
|
| 55.
|
Fry, C. J.,
and Peterson, C. L.
(2001)
Curr. Biol.
11,
R185-R197[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Strahl, B. D.,
and Allis, C. D.
(2000)
Nature
403,
41-45[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Agalioti, T.,
Lomvardas, S.,
Parekh, B.,
Yie, J.,
Maniatis, T.,
and Thanos, D.
(2000)
Cell
103,
667-678[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Hassan, A. H.,
Neely, K. E.,
and Workman, J. L.
(2001)
Cell
104,
817-827[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Vitolo, J. M.,
Thiriet, C.,
and Hayes, J. J.
(2000)
Mol. Cell. Biol.
20,
2167-2175[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike